Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
156 articles with Selecta Biosciences
-
Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy
12/9/2013
-
Selecta Biosciences, Inc. Announces Allowance Of The First In A Series Of Patents On The Induction Of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies
12/9/2013
-
Selecta Biosciences, Inc. Distinguished as World Economic Forum Technology Pioneer 2014
8/27/2013
-
Sanofi (France) Deal Could Net Selecta Biosciences, Inc. $900 Million
11/29/2012
-
Selecta Biosciences, Inc. Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation
5/9/2012
-
Selecta Biosciences, Inc. Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention
11/21/2011
-
Selecta Biosciences, Inc. Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies
10/27/2011
-
Selecta Biosciences, Inc. Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria
8/31/2011
-
Selecta Biosciences, Inc. Appoints Takashi Kei Kishimoto, Ph.D., as Chief Scientific Officer
8/31/2011
-
The Juvenile Diabetes Research Foundation and Selecta Biosciences, Inc. Enter Research Collaboration for Vaccines for Type 1 Diabetes
6/9/2011
-
Selecta Biosciences, Inc. Appoints Peter Keller as Vice President of Business Development and Alliance Management
6/9/2011
-
Selecta Biosciences, Inc. Receives $3 Million from National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) to Develop Nicotine Vaccine for Smoking Cessation
8/16/2010
-
Former Solvay Pharmaceuticals, Inc. Chief Werner Cautreels, Ph.D. Takes Lead Role at Startup Selecta Biosciences, Inc.
8/16/2010
-
Selecta Biosciences, Inc. Closes $15 Million Series C Financing
4/5/2010
-
Selecta Biosciences, Inc. Co-Founder Named 2009 Mass High Tech All Star
10/30/2009
-
Selecta Biosciences, Inc. Closes $15.1M Series B Financing
2/25/2009